Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study.
Saved in:
| Title: | Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study. |
|---|---|
| Authors: | Kostov AM; Department of Surgical Pathology, Zealand University Hospital, Sygehusvej 9-11, 4000, Roskilde, Denmark., Jensen MB; Danish Breast Cancer Cooperative Group, Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Ejlertsen B; Danish Breast Cancer Cooperative Group, Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Thomassen M; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.; Human Genetics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Clinical Genome Center, University of Southern Denmark and Region of Southern Denmark, Odense, Denmark., Rossing M; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Pedersen IS; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; Department of Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Petersen AH; Department of Clinical Genetics, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark., Christensen LL; Department of Molecular Medicine (MOMA), Aarhus University Hospital, Aarhus, Denmark., Wadt KAW; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Berrocal-Almanza LC; Oncology Outcomes Research, AstraZeneca, Cambridge, UK., Miranda M; Oncology Outcomes Research, AstraZeneca, Cambridge, UK., Lænkholm AV; Department of Surgical Pathology, Zealand University Hospital, Sygehusvej 9-11, 4000, Roskilde, Denmark. anlae@regionsjaelland.dk.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. anlae@regionsjaelland.dk. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2025 Jul; Vol. 212 (2), pp. 309-323. Date of Electronic Publication: 2025 May 23. |
| Publication Type: | Journal Article; Observational Study |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-7217 |
|---|---|
| DOI: | 10.1007/s10549-025-07726-2 |
